لا تُقدم XM خدماتها لمواطني الولايات المتحدة الأمريكية.
G
G

GSK


أخبار

Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO

Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 mln valuation in US IPO Sept 6 (Reuters) - Zenas BioPharma, which is developing immunology-based therapies, said on Friday it is targeting a valuation of as much as $689.7 million in its initial public offering in the United States. The company, backed by drugmaker Bristol-Myers Squibb BMY.N , is looking to raise as much as $211.7 million by offering 11.76 million shares priced between $16 and $18 each.
C
G

GSK's asthma drug Nucala meets main goal in study on treating smoker's lungs

UPDATE 1-GSK's asthma drug Nucala meets main goal in study on treating smoker's lungs Adds detail on Nucala from paragraph 3 onwards Sept 6 (Reuters) - British drugmaker GSK GSK.L said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or smoker's lungs.
G

GSK's asthma drug Nucala meets main goal in smoker's lungs trial

GSK's asthma drug Nucala meets main goal in smoker's lungs trial Sept 6 (Reuters) - British drugmaker GSK GSK.L on Friday announced positive results from its late-stage trial of asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD), also known as smoker's lungs. The company said the trial met its main goal in reducing the annualised rate of moderate or severe exacerbations, compared with a placebo, in COPD patients treated for up to 104 weeks.
G

GSK Announces Positive Phase III Results For Nucala In COPD

BRIEF-GSK Announces Positive Phase III Results For Nucala In COPD Sept 6 (Reuters) - GSK plc GSK.L : GSK PLC - POSITIVE PHASE III RESULTS FOR NUCALA IN COPD GSK PLC - ANNOUNCES POSITIVE RESULTS FROM PHASE III TRIAL OF NUCALA IN COPD GSK PLC - PRIMARY ENDPOINT MET WITH SIGNIFICANT REDUCTION IN EXACERBATIONS GSK PLC - PRELIMINARY SAFETY RESULTS CONSI
G

EMA Approves GSK's Arexvy For Adults Aged 50-59 At Increased Risk

BRIEF-EMA Approves GSK's Arexvy For Adults Aged 50-59 At Increased Risk Aug 29 (Reuters) - GSK plc GSK.L : GSK PLC - EMA APPROVAL ON AREXVY FOR 50-59 AT RISK GSK PLC - EMA APPROVAL ON AREXVY FOR 50-59 AT RISK GSK PLC - FILED REGULATORY SUBMISSIONS TO EXTEND AREXVY USE TO ADULTS 50-59 IN JAPAN AND OTHER GEOGRAPHIES Source text for Eikon: ID:nRSc0515
G

UK Stocks-Factors to watch on Aug 28

UPDATE 1-UK Stocks-Factors to watch on Aug 28 Adds new items, updates futures Aug 28 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0.2%. * FRASERS: British sportswear and apparel retailer Frasers FRAS.L said it has purchased a 14.65% stake in Australian sportswear retailer Accent Group Ltd. * FCA: Britain's Financial Conduct Authority said it would launch a market study into pure protection insurance product sales, amid fears that the desig
G
U

GSK Says Bepirovirsen granted SENKU designation in Japan

BRIEF-GSK Says Bepirovirsen granted SENKU designation in Japan Aug 28 (Reuters) - GSK plc GSK.L : SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN CONFIRMATORY PHASE III PROGRAMME B-WELL ONGOING Source text for Eikon: ID:nRSb8953Ba Further company coverage: GSK.L
G

GSk's Nucala Approved In Japan For Use In CRSwNP

BRIEF-GSk's Nucala Approved In Japan For Use In CRSwNP Aug 28 (Reuters) - GSK plc GSK.L : GSK PLC - NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP GSK: MEPOLIZUMAB IS APPROVED IN JAPAN TO TREAT BRONCHIAL ASTHMA IN CHILDREN AGED 6-YEAR OR OLDER AND IN ADULTS WITH REFRACTORY ASTHMA Source text for Eikon: ID:nRSb9634Ba Further company coverage: GSK.L
G

UK Stocks-Factors to watch on Aug 28

UK Stocks-Factors to watch on Aug 28 Aug 28 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0.1%. * GSK: Delaware's highest court said it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. * PRUDENTIAL: Prudential PRU.L reported an 9% rise in first-half operating profit, backed by a strong rebound of new sales in Hong Kong after the removal
B
G
U

British Business - Aug 28

PRESS DIGEST-British Business - Aug 28 Aug 28 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Delaware's highest court will hear an appeal by GSK GSK.L and rival drugmakers seeking to end more than 70,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer .
B
E
G
H
N

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

UPDATE 3-Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Adds response from plaintiffs' attorneys in paragraph 5 By Brendan Pierson Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer.
G
P
S

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits

Delaware top court will hear drugmakers' appeal to end Zantac lawsuits Aug 27 (Reuters) - Delaware's highest court said on Tuesday it will hear an appeal by GSK GSK.L and other drugmakers seeking to end more than 70,000 lawsuits claiming discontinued heartburn drug Zantac caused cancer. GSK, Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim are asking the court to overturn an order by a lower court judge allowing plaintiffs in the lawsuits to offer expert testimony on the alleged cancer lin
G
P
S

British Business - Aug. 26

PRESS DIGEST-British Business - Aug. 26 Aug 26 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - The British Financial Conduct Authority has warned unregulated firms that they cannot help to arrange investment deals for private companies without regulatory permissions.
A
G
M

Ozempic on Wall Street's list for 2027 Medicare drug negotiations

ANALYSIS-Ozempic on Wall Street's list for 2027 Medicare drug negotiations Novo Nordisk, Pfizer, GSK drugs likely to be in 2027 Medicare negotiations Most drugs already discounted, limited impact seen on Big Pharma Analysts expect price cuts to have bigger bite starting in 2028 By Michael Erman NEW YORK, Aug 23 (Reuters) - Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026 , Wall Street analysts are betting on a 2027 list that will include Novo N
G
P
T

GSK Gets FDA Breakthrough Therapy Designation For GSK5764227

BRIEF-GSK Gets FDA Breakthrough Therapy Designation For GSK5764227 Aug 20 (Reuters) - GSK plc GSK.L : GSK PLC - B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION GSK PLC - RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR GSK5764227 Source text for Eikon: ID:nRST0175Ba Further company coverage: GSK.L
G

GSK to seek dismissal of Florida case against heartburn drug Zantac

GSK to seek dismissal of Florida case against heartburn drug Zantac Aug 16 (Reuters) - British drugmaker GSK GSK.L said on Friday it would seek a dismissal of an upcoming Zantac case in Florida, where plaintiffs alleged that its discontinued heart burn drug had caused prostate cancer. The move followed a Florida court ruling on Thursday in favour of GSK and other defendants.
G
P
S

GSK Says Florida Court Rules In Favor Of GSK In Zantac Litigation

BRIEF-GSK Says Florida Court Rules In Favor Of GSK In Zantac Litigation Aug 16 (Reuters) - GSK plc GSK.L : STATEMENT: ZANTAC (RANITIDINE) LITIGATION FLORIDA COURT RULES IN FAVOR OF GSK IN ZANTAC LITIGATION WELCOMES FLORIDA STATE COURT DAUBERT RULING CONTINUES TO DEFEND ITSELF INCLUDING AGAINST ALL REMAINING CLAIMS IN OTHER JURISDICTIONS Source text
G

German panel endorses GSK, Pfizer RSV vaccines for elderly

German panel endorses GSK, Pfizer RSV vaccines for elderly FRANKFURT, Aug 8 (Reuters) - Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV. The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L , should be administered ideally in September or October before the cold
A
G
P
S

UK Stocks-Factors to watch on August 8

UPDATE 1-UK Stocks-Factors to watch on August 8 Adds new items, updates futures Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.3%. * BARRATT-REDROW DEAL: UK's competition regulator said its phase 1 review into homebuilder Barratt's BDEV.L 2.52 billion pound ($3.21 billion) all-stock deal to buy smaller rival Redrow RDW.L had raised concerns in the local area around a Barratt development.
A
A
B
B
B
B
F
G
I
I
P
P
R
R
S
S

UK Stocks-Factors to watch on August 8

UK Stocks-Factors to watch on August 8 Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.5%. * GSK: The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
A
A
B
B
B
D
F
G
H
I
I
L
P
P
P
R
S
S
U



الشروط

الأصول الشائعة

إخلاء المسؤولية: تتيح كيانات XM Group خدمة تنفيذية فقط والدخول إلى منصة تداولنا عبر الإنترنت، مما يسمح للشخص بمشاهدة و/أو استخدام المحتوى المتاح على موقع الويب أو عن طريقه، وهذا المحتوى لا يراد به التغيير أو التوسع عن ذلك. يخضع هذا الدخول والاستخدام دائماً لما يلي: (1) الشروط والأحكام؛ (2) تحذيرات المخاطر؛ (3) إخلاء المسؤولية الكامل. لذلك يُقدم هذا المحتوى على أنه ليس أكثر من معلومات عامة. تحديداً، يرجى الانتباه إلى أن المحتوى المتاح على منصة تداولنا عبر الإنترنت ليس طلباً أو عرضاً لدخول أي معاملات في الأسواق المالية. التداول في أي سوق مالي به مخاطرة عالية برأس مالك.

جميع المواد المنشورة على منصة تداولنا مخصصة للأغراض التعليمية/المعلوماتية فقط ولا تحتوي - ولا ينبغي اعتبار أنها تحتوي - على نصائح أو توصيات مالية أو ضريبية أو تجارية، أو سجلاً لأسعار تداولنا، أو عرضاً أو طلباً لأي معاملة في أي صكوك مالية أو عروض ترويجية مالية لا داعي لها.

أي محتوى تابع للغير بالإضافة إلى المحتوى الذي أعدته XM، مثل الآراء، والأخبار، والأبحاث، والتحليلات والأسعار وغيرها من المعلومات أو روابط مواقع تابعة للغير وواردة في هذا الموقع تُقدم لك "كما هي"، كتعليق عام على السوق ولا تعتبر نصيحة استثمارية. يجب ألا يُفسر أي محتوى على أنه بحث استثماري، وأن تلاحظ وتقبل أن المحتوى غير مُعدٍ وفقاً للمتطلبات القانونية المصممة لتعزيز استقلالية البحث الاستثماري، وبالتالي، فهو بمثابة تواصل تسويقي بموجب القوانين واللوائح ذات الصلة. فضلاً تأكد من أنك قد قرأت وفهمت الإخطار بالبحوث الاستثمارية غير المستقلة والتحذير من مخاطر المعلومات السابقة، والذي يمكنك الاطلاع عليه هنا.

تحذير المخاطر: رأس مالك في خطر. المنتجات التي تستخدم الرافعة قد لا تكون مناسبة للجميع. يرجى الاطلاع على تنبيه المخاطر.